Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma

Autor:	Musab A Alsubaie, Abdullah A. Alesa, Muhammad Anwar Khan, Mubarak Al-Mansour, Saif Abdulghani Alghamdi
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	0301 basic medicine Cancer Research medicine.medical_specialty HBsAg Lymphoma Epidemiology medicine.disease_cause Gastroenterology lcsh:RC254-282 lcsh:Infectious and parasitic diseases 03 medical and health sciences 0302 clinical medicine Internal medicine hemic and lymphatic diseases medicine lcsh:RC109-216 Progression-free survival Hepatitis Hepatitis B virus Hepatitis B virus reactivation business.industry virus diseases Retrospective cohort study Diffuse large B-cell lymphoma medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens digestive system diseases Regimen 030104 developmental biology Infectious Diseases Oncology 030220 oncology & carcinogenesis business Research Article
Zdroj:	Infectious Agents and Cancer, Vol 13, Iss 1, Pp 1-7 (2018) Infectious Agents and Cancer
ISSN:	1750-9378
DOI:	10.1186/s13027-018-0190-9
Popis:	Background Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy. Methods This retrospective cohort study was conducted at Princess Noorah Oncology Center, Jeddah by reviewing all medical records of 172 DLBCL diagnosed patients and recieved Rituximab-containing chemotherapy dated from January 2009 to February 2016. Results Out of 172 patients, 53 were found positive in hepatitis serology. The 12 of those were HBsAg-positive and 41 were HBcAb-positive. Hepatitis reactivation was observed in 1% of the patients (i.e., 2 out of 172) and both of them were HBsAg-positive. Thus, the risk of hepatitis reactivation among the HBsAg-positive patients was 17% (i.e., 2 out of 12). The predicted 3-year PFS for HBsAg-positive and HBcAb-positive were 52% (± 8%), while 76% (± 4) for HBsAg-negative and HBcAb-negative patients. On the other hand, the predicted 3-year OS for HBsAg and HBcAb-negative group is 93% (±3) while for HBsAg-positive and HBcAb-positive is 77% (±7), respectively. Conclusion The present study demonstrated a low HBV reactivation rate of 1% exclusively in 2 patients with HBsAg-positive status diagnosed with DLBCL and receiving R-CHOP chemotherapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee8cb47cecf00443dd76e69c666abe0 http://link.springer.com/article/10.1186/s13027-018-0190-9 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.